ITUSVILLE, N.J. (AP) - Diversified health care and consumer products maker Johnson & Johnson said Tuesday its Ortho-McNeil Neurologics Inc. division was granted a preliminary injunction against Mylan Laboratories Inc. preventing it from launching a generic version of topiramate before a final court ruling on the validity of the patent.
Judge Stanley R. Chesler of the U.S. District Court for the District of New Jersey in Newark, N.J., granted the injunction on Monday for Ortho-McNeil's Topamax brand.
Topamax is used for epilepsy, Lennox Gastaut syndrome and migraine headaches.
The preliminary injunction will be in effect until the district court has rendered a final decision on the validity of the Topamax patent, which expires in September 2008.
A trial date has not yet been set.
A company spokesman for Mylan was not immediately available for comment.
Shares of Johnson & Johnson fell 44 cents to $68.66 in afternoon trading on the New York Stock Exchange, while shares of Mylan shed 65 cents, or nearly 3 percent, to $21.25.